NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple preclinical models to
enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in
diseases like ischemic optic neuropathy/optic nerve stroke. We hypothesize that CNTF delivery
to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement
(improve vision indices) in ischemic optic neuropathy. Patients in the trial will receive an
NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to
evaluate safety and efficacy.